Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human FcɛRI+cells
A. GENOVESE
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Search for more papers by this authorV. PATELLA
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Search for more papers by this authorG. DE CRESCENZO
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Search for more papers by this authorA. DE PAULIS
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Search for more papers by this authorG. SPADARO
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Search for more papers by this authorCorresponding Author
G. MARONE
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Professor G. Marone, Divisione di Immunologia, Clinica Facoltà di Medicina. Via S. Pansini 5. 80131 Napoli. Italy.Search for more papers by this authorA. GENOVESE
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Search for more papers by this authorV. PATELLA
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Search for more papers by this authorG. DE CRESCENZO
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Search for more papers by this authorA. DE PAULIS
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Search for more papers by this authorG. SPADARO
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Search for more papers by this authorCorresponding Author
G. MARONE
Division of Clinical Immunology and Allergy, University of Naples Federico II School of Medicine, Naples, Italy
Professor G. Marone, Divisione di Immunologia, Clinica Facoltà di Medicina. Via S. Pansini 5. 80131 Napoli. Italy.Search for more papers by this authorSummary
Background Loratadine, a novel histamine H1-receptor antagonist, is effective in the treatment of patients with seasonal and perennial rhinitis and some allergic skin disorders. Histamine and other chemical mediators are synthesized and immunologically released by human peripheral blood basophils and tissue mast cells (FcɛRI+ cells).
Objective To evaluate the effects of loratadine and its main metabolite, desethoxylcarbonyl-loratadine (des-loratadine), on the immunological release of preformed (histamine and tryptase) and de novo synthesized mediators (leukotriene C4: LTC4 and prostaglandin D2: PGD2) from human FcɛRI+ cells.
Methods Human FcɛRI+ cells purified from peripheral blood and from skin (HSMC) and lung tissue (HLMC) were preincubated with loratadine and des-loratadine before immunological challenge with Der p 1 antigen or anti-FcɛRI. The release of preformed mediators (histamine and tryptase) and de novo synthesized eicosanoids was evaluated in the supernatants of human FcRI+ cells.
Results Preincubation (15m in, 37°C) of purified (36–74%) basophils with loratadine (3 × 10–6–10–4M) and des-loratadine before Der p 1 antigen or anti-FcɛRI challenge concentration-dependency (5–40%) inhibited the release of histamine and LTC4. Loratadine (3 × 10–6–l0–4M) and des-loratadine also inhibited (10–40%) histamine, LTC4, and PGD2 release from purified HLMC (16–68%) activated by anti-FcɛRI. Loratadine (3 × 10–6–10–4M) and des-loratadine caused concentration-dependent inhibition (10–40%) of histamine, tryptase. LTC4, and PGD2 release from purified HSMC (24– 72%) immunologically challenged with anti-FcɛRI.
Conclusion These results indicate that loratadine and its main metabolite have anti- inflammatory activity by inhibiting the release of preformed and de novo synthesized mediators from human FcɛRI+ cells.
References
- 1 Galli SJ. New concepts about the mast cell. N Engl J Med 1993; 328: 257–265.
- 2 Redington AE, Polosa R, Walls AF, Howarth PH, Holgate ST. Role of mast cells and basophils in asthma. In: G Marone, (Ed): Human basophils and mast cells: Clinical aspects Basel Karger, 1995; 62: 22–59.
- 3 Bochner BS, Licthenstein LM. Anaphylaxis. N Engl J Med 1991; 324: 1785–90.
- 4 Bradding P, Feather IH, Howarth PH et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992; 176: 1381–6.
- 5 Brunner T, Heusser CH, Dahinden CA. Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J Exp Med 1993; 177: 605–11.
- 6 Gauchat JF, Henchoz S, Mazzel G et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993; 365: 340–3.
- 7 Patella V, Marinò I, Lamparter B et al. Human heart mast cells. Isolation, purification, ultrastructure and immunologic characterization. J Immunol 1995; 154: 2855–65.
- 8 Casolaro V, Spadaro G, Marone G. Human basophil releasability. VI, Changes in basophil releasability in patients with allergic rhinitis or bronchial asthma. Am Rev Respir Dis 1990; 142: 1108–1111.
- 9 de Paulis A, Cirillo R, Ciccarelli A, Condorelli M, Marone G. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human FcɛRI+ cells. J Immunol 1991; 146: 2374–81.
- 10 Triggiani M, Schleimer RP, Warner JA, Chilton FH. Differential synthesis of l-acyl-2-acetyl-sn-glycero-3-phosphocholine and platelet-activating factor by human inflammatory cells. J Immunol 1991; 147: 660–6.
- 11 Hide M, Francis DM, Grattan CEH et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328: 1599–604.
- 12 Guo CB, Liu MC, Galli SJ et al. Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils. Am J Respir Cell Mol Biol 1994; 10: 384–90.
- 13 Schwartz LB. Tryptase, a mediator of human mast cells. J Allergy Clin Immunol 1990; 86: 594–598.
- 14 Fauler J, Neumann C, Tsikas D, Frölich J. Enhanced synthesis of cysteinyl leukotrienes in psoriasis. J Invest Dermatol 1992; 99: 8–11.
- 15 Manning PJ, Watson RM, Margolskee DJ et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990; 323: 1736–9.
- 16 Herxheimer H. Antihistamines in bronchial asthma, Br Med J 1949; 2 901–5.
- 17 Holgate ST, Finnerty JP. Antihistamines in asthma. J Allergy Clin Immunol 1989; 83: 537–47.
- 18 Howarth PH. Histamine and asthma: an appraisal based on specific H1-receptor antagonism. Clin Exp Allergy 1990; 20 (suppl 2): 31–41.
- 19 Bousquet J, Godard Ph, Michel FB Antihistamines in the treatment of asthma. Eur Respir J 1992; 5: 1137–42.
- 20 Del Carpio J, Kabbash L, Turenne Y et al. Efficacy and safety of loratadine (l0mg once daily), lerfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84: 741–6.
- 21 Gutkowski A, Bedard P, Del Carpio J et al. Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1988; 81: 902–7.
- 22 Lichtenstein LM, Gillespie E. The effects of the H1 and H2 antihistamines on ‘allergic’ histamine release and its inhibition by histamine. J Pharm Exp Therap 1975; 192: 441–50.
- 23
Church MK,
Gradidge CF.
Inhibition of histamine release from human lung in vitro by antihistamines and related drugs.
Br J Pharmac
1980; 9: 663–7.
10.1111/j.1476-5381.1980.tb07919.x Google Scholar
- 24 Marone G, Columbo M, Polo S, Condorelli M. Inhibition of histamine release from human basophils in vitro by calmodulin antagonists. Clin Immunol Immunopathol 1983; 28: 334–40.
- 25 Nabe M, Agrawal DK, Sarmiento EU, Townley RG. Inhibitory effect of terfenadine on mediator release from human blood basophils and eosinophils. Clin Exp Allergy 1989; 19: 515–20.
- 26 Little MM, Casale TB. Azelastine inhibits IgE-mediated human basophil histamine release. J Allergy Clin Immunol 1989; 83: 862–5.
- 27 Okayama Y, Benyon RC, Lowman MA, Church MK. In vitro effects of H1-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin. Allergy 1994; 49: 246–53.
- 28 Boner AL, Miglioranzi P, Richelli C, Marchesi E, Andreoli A. Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis. Allergy 1989; 44: 437–41.
- 29 Dockhorn RJ, Bergner A, Connell JT, Falliers CJ, Grabiec SV, Weiler JM, Shellenberger MK. Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis. Ann Allergy 1987; 58: 407–11.
- 30 Monroe EW, Fox RW, Green AW, Izuno GT, Bernstein DI, Pleskow WW, Willis I, Brigante JR. Efficacy and safety (10 mg once daily) in the management of idiopathic chronic urticaria. J Am Acad Dermatol 1988; 19: 138–9.
- 31 Temple DM, McCluskey M. Loratadine, an antihistamine, blocks antigen- and ionophore – induced leukotriene release from human lung in vitro. Prostaglandins 1988; 35: 549–54.
- 32 Kleine-Tebbe J, Josties C, Frank G et al. Inhibition of IgE- and non-lgE-mediated histamine release from human basophil leucocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine. J Allergy Clin Immunol 1994; 93: 494–500.
- 33 Miadonna A, Milazzo N, Lorini M. Marchesi E, Tedeschi A. Inhibitory effect of the H1 antagonist loratadine on histamine release from human basophils. Int Arch Allergy Immunol 1994; 105: 12–17.
- 34 Bousquet J, Lebel B, Chanal I, Morel A, Michel F-B. Anti- allergic activity of H1-receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol 1988; 82: 881–887.
- 35 Greiff L, Persson CGA, Svensson C, Enander I, Andersson M. Loratadine reduces allergen-induced mucosal output of α2-macroglobulin and tryptase in allergic rhinitis. J Allergy Clin Immunol 1995; 96: 97–103.
- 36 Ciprandi G, Buscaglia S, Pesce GP, Marchesi E, Canonica GW. Protective effect of loratadine on specific conjunctival provocation test. Int Arch Allergy Appl Immunol 1991; 96: 344–347.
- 37 Rische F, Hakim J, Mallamaci M, Griffin M, Pilson B, Tobkes N, Lin P, Danho W, Kochan J, Chizzonite R. High affinity human IgE receptor (FcɛRI). Analysis of functional domains of the α-subunit with monoclonal antibodies. J Biol Chem 1991; 266: 11245–11251.
- 38 Kusner EJ, Marks RL, Aharony D, Krell RD. Inhibition by REV-509 of leukotriene release from guinea-pig and human lung tissue in vitro. Biochem Pharmacol 1989; 38: 4183–4189.
- 39 Patella V, Casolaro V, Ciccarelli A, Pettit GR, Columbo M, Marone G. The antineoplastic bryostatins affect human basophils and mast cells differently. Blood 1995; 85: 1272–1281.
- 40 Casolaro V, Meliota S, Marino O, Patella V, de Paulis A, Guidi G, Marone G. Nimesulide. a sulfonanilide non-steroidal anti- inflammatory drug, inhibits mediator release from human basophils and mast cells. J Pharmacol Exp Ther 1993; 267: 1375–1385.
- 41 Benyon RC, Lowman MA, Church MK. Human skin mast cells: their dispersion, purification, and secretory characterization. J Immunol 1987; 138: 861–867.
- 42 Siraganian RP. An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal Biochem 1974; 57: 383–394.
- 43 Snedecor GW, Cochran WG. Statistical methods. The Iowa State University Press 1980.
- 44 Marone G, Kagey-Sobotka A, Lichtenstein LM. IgE-mediated histamine release from human basophils: differences between antigen E- and anti-lgE-induced secretion. Int Archs Allergy Appl Immunol 1981; 65: 339–348.
- 45 Quinti I, Brozek C, Wood N, Geha RS, Leung DYM. Circulating IgG autoantibodies to IgE in atopic syndromes. J Allergy Clin Immunol 1986; 77: 586–594.
- 46 Grattan CEH, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991; 21: 695–704.
- 47 Marone G, Casolaro V, Paganelli R, Quinti I. IgG anti-IgE from atopic dermatitis induces mediator release from hasophils and mast cells. J Invest Dermatol 1989; 93: 246–252.
- 48 Hilbert J, Radwanski E, Weglein R, Luc V, Perentesis G, Symchowicz S, Zampaglione N. Pharmacokinetics and dose proportionality of loratadine. J Clin Pharmacol 1987; 27: 694–698.
- 49 Barenholtz HA, McLeod DC. Loratadine: a nonsedating antihistamine with once-daily dosing. D1CP 1989; 23: 445–450.
- 50 Stellate C, Cirillo R, de Paulis A, Casolaro V, Patella V, Mastronardi P, Mazzarella B, Marone G: Human basophil/ mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release. Anesthesiology 77: 932, 1992.
- 51 Letari O, Miozzo A, Sab A, Bolla M, Rovati GE, Nicosia S, Folco GC. Loratadine inhibits calcium increase in peritoneal macrophages and leukotriene release in human bronchial strips. Allergy 1992; 47 (suppl 12).
Citing Literature
